DR6 was revealed to be a risk factor for CKD in RA patients and, therefore, might be useful for the prevention of CKD in RA patients with DR6: newly diagnosed RA patients should be genotyped, and RA patients with DR6 should be under the strict management of blood pressure or blood glucose levels. Here, TNFRSF21 is linked to chronic kidney disease.